Proud to share our work on the immunotherapeutic potential of anti-GD2 antibody Naxitamab in breast cancer, now published in NPJ Breast Cancer. This research led to a DoD-funded clinical trial at MD Anderson and VCU. #BreastCancer @MDAndersonNews https://t.co/bEorFXb0rd
New study reveals GD3 synthase (GD3S), a key anti-apoptotic factor in breast cancer. It is upregulated by mutant p53 and overrides p53-induced cell death by enhancing mitochondrial activity. Targeting GD3S may offer new hope. @MDAndersonNews#breastcancer https://t.co/SlSvYX7bB9.
A 1,000,000th reminder the crucial importance of basic research. Ambros and Ruvkun were looking into understanding nematode genetics and development, not looking for a drug, and ended up opening an entire new area in biology
Database of 316 funding opportunities/fellowships for POSTDOC fellows.
For each entry, we provide description, link to funder, deadline, $ amount, discipline/field, and eligibility criteria (e.g. citizenship).
Download it here: https://t.co/EbTahdzJ9X
After Shunning Scientist, University of Pennsylvania Celebrates Her Nobel Prize
School that once demoted Katalin Karikó and cut her pay has made millions of dollars from patenting her work
@GZuckerman writes @WSJ
https://t.co/mZDSNj6JeQ
Visiting my PhD alma-mater @aiims_newdelhi reuniting with my esteemed mentor & wonderful colleagues filled my heart with gratitude and nostalgia. The warmth of their welcome and the reminiscing of old times made the experience truly unforgettable.
Together, through unwavering trust, collaboration, and shared vision, we unleash the extraordinary potential hidden within our united fronts @MDAndersonNews. Embracing today's success as a catalyst for the even greater triumphs that lie ahead..
Excited to present our data demonstrating Naxitamab, a humanized anti-GD2 antibody, inhibits GD2–mediated immunosuppression in breast cancer. #AACR2023@AACR#AACR@MDAndersonNews
Being rigorous does not have to mean being cruel.
We can have high standards and also be kind in how we communicate them.
We can choose to support people in achieving their best rather than tearing them down when they fall short.
President Biden reignited the Cancer Moonshot – with the goal of cutting the cancer death rate by at least half over the next 25 years and ending cancer as we know it.
We're excited to share the 1st clinical experience delivering intracranial B7-H3 #CARTcells to treat #DIPG in @CD_AACR, a journal of the @AACR. #1: on behalf of @seattlechildren & @SCTherapeutics, we are humbled by our patients' trust and bravery. (1/2)
https://t.co/UmNcuPwC8Z
New #JITC article: Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma https://t.co/WUwHBe8vJg @LandonBrownMD@MattZibelman@TiansterZhang
2nd year in a row, I’d the honor of guiding an extremely bright summer intern from Augustana College, IL. With no prior exposure they’d learned everything about research in just 10 wks. Hope they keep their enthusiasm for science @zoeee_a9 & Lindsay. Thank you @MDAndersonNews!